Report of Foreign Issuer (6-k)
November 04 2019 - 07:31AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
under
the Securities Exchange Act of 1934
For
the month of: November 2019
Commission
file number: 001-36578
ENLIVEX
THERAPEUTICS LTD.
(Translation
of registrant’s name into English)
14
Einstein Street, Nes Ziona, Israel 7403618
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
On
November 4, 2019, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”),
issued a press release with respect to interim safety and efficacy data from the Company’s ongoing trial of off-the-shelf
Allocetra in patients with severe sepsis. A copy of such press release is furnished as Exhibit 99.1 to this Report on Form 6-K
and incorporated herein by reference.
Exhibit
No.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Enlivex
Therapeutics Ltd.
|
|
(Registrant)
|
|
|
|
By:
|
/s/
Shai Novik
|
|
Name:
|
Shai
Novik
|
|
Title:
|
Executive
Chairman
|
Date:
November 4, 2019
2
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Feb 2024 to Mar 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Mar 2023 to Mar 2024